Xander Lee

Cooley advised D3 Bio – an emerging global biotechnology company that focuses on discovery, development and registration of innovative cancer drugs – on the close of its $62 million Series A+ financing.

Cooley advised ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for patients with cancer, on its definitive agreement to be acquired for $1.8 billion in an all-cash transaction by Genmab (NASDAQ: GMAB), a dual-listed, international biotechnology company that creates and develops differentiated antibody therapeutics to fight against cancer and other serious diseases.

Cooley advised the underwriters of Viking Therapeutics – a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders – on its $632.5 million public offering of common stock.

Cooley advised ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for patients with cancer, on its $112 million oversubscribed Series B financing.

Cooley advised Blue Owl Capital, a top asset manager redefining alternatives, on its strategic investment a $300 million royalty financing and a $450 million credit facility in BridgeBio Pharma, a commercial-stage biopharmaceutical company focused on genetic diseases and cancers.